Mark G. Kris, MD, FASCO shares an overview of existing treatment options for patients with stage I-III non-small cell lung cancer.
Post-Conference Perspectives: ctDNA for MRD in Lung Cancer
Practical advice on monitoring options for patients with NSCLC treated with definitive radiation therapy or surgery.
Dr. Mark Kris shares insight on ctDNA and its use in detecting MRD in NSCLC.
A comprehensive review of data presented at ASCO 2022 on ctDNA and MRD detection in NSCLC.
A thoracic oncology expert provides perspective on ctDNA as a tool and its future as part of the NSCLC landscape.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5